Turn Therapeutics, a clinical-stage biotechnology company focused on dermatology, wound care, and infectious disease, announced it expects its common stock to begin trading on the Nasdaq Global Market under ticker symbol "TTRX" on October 8, 2025. The announcement follows the company's filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for its proposed public listing.
Clinical Pipeline and FDA Approvals
The company has already achieved significant regulatory milestones, having received three FDA clearances for its proprietary wound and dermatology formulations. Turn is currently advancing late-stage clinical programs targeting two key dermatological conditions: eczema and onychomycosis, a fungal nail infection that affects millions of patients worldwide.
Global Health Initiatives
Beyond its core dermatology and wound care programs, Turn Therapeutics is pursuing global health initiatives focused on thermostable vaccine delivery. These programs are specifically designed to serve underserved areas worldwide, reflecting the company's commitment to public health innovation in regions with limited cold-chain infrastructure.
Public Market Preparation
In preparation for its public debut, Turn Therapeutics hosted a live Open Investor Session on September 17, presented by Bradley Burnam, the company's Founder and CEO. The webcast was made available through the company's website and included a recording for follow-up access.
Turn Therapeutics operates as a registered DBA of Global Health Solutions, Inc., a Delaware corporation. The company is headquartered at 250 N. Westlake Blvd., Westlake Village, California.
Market Positioning
The company's diversified approach spans multiple therapeutic areas, with established products in dermatology and wound care, alongside development programs in infectious disease. This positioning allows Turn to address various unmet medical needs across different patient populations, from common skin conditions to global health challenges in vaccine delivery.
